We report two children who presented with cough and shortness of breath 7-8 months after a matched sibling stem cell transplant (SCT) for chronic myelogenous leukemia and myelodysplastic syndrome, respectively. Pulmonary function tests (PFTs) revealed severe airways obstruction (AO). However, radiographic investigations showed no serious abnormalities in the early phase and open lung biopsy revealed only mild lymphocytic bronchiolitis and bronchiolitis obliterans consistent with pulmonary graft-versus-host disease (GVHD). Despite administration of bronchodilators and various immunosuppressive agents obstructive lung disease progressed to pulmonary failure in patient 1, whereas stabilization of the clinical course was observed in patient 2. Serial PFTs were the best predictor of the clinical course in contrast to radiographic and histologic findings. It is concluded that PFTs should be performed repeatedly in pediatric patients after allogeneic SCT with the aim of diagnosing GVHD-associated AO in the subclinical phase. Progressive post-transplant AO necessitates prompt initiation of intensive immunosuppressive therapy in order to stop the underlying immunopathologic process even in the absence of severe radiographic and histologic findings.
skin, liver, gastrointestinal tract and lungs. [5] [6] [7] [8] [9] Mild and subclinical post-transplant ventilatory defects are commonly seen after SCT. [10] [11] [12] In contrast, severe airways obstruction (AO) after SCT is a major and clinically significant complication of chronic GVHD causing high morbidity and mortality. 9, [13] [14] [15] [16] [17] [18] Although post-transplant AO is histologically often associated with bronchiolitis obliterans (BO), various other patterns of GVHD-related histopathologic changes of the lungs have been described. [18] [19] [20] Pulmonary function tests (PFTs) in patients with lung GVHD show abnormal ventilatory function either of the restrictive or the obstructive pattern or a combined ventilatory defect depending on the underlying histopathologic process. 16, 17, 20 However, clinical presentation of lung GVHD is uniform. Most patients have non-productive cough and shortness of breath or both as their initial symptoms. We present the clinical courses, radiographic and histopathologic findings and PFTs of two children with severe AO related to pulmonary GVHD.
Case reports

Patient 1
A 14-year-old boy with Philadelphia chromosome-positive chronic myelogenous leukemia was referred for SCT after 6 months therapy with hydroxyurea and interferon alpha2c. Conditioning consisted of busulfan (BU) 160 mg daily on days Ϫ9 to Ϫ6 (16 mg/kg total) and cyclophosphamide (CY) 1600 mg daily on days Ϫ5 to Ϫ2 (160 mg/kg total). He received an allogeneic bone marrow (BM) transplant from his HLA-identical sister (2.94 × 10 8 NC (nucleated cells)/kg). Pretransplant chest radiograph and PFTs were normal (Table 1) . He reached 1.0 × 10 9 /l leukocytes on day +15. GVHD prophylaxis consisted of cyclosporin A (CsA) and three doses of methotrexate (MTX) on days +1, +3 and +18. The early post-transplant course was complicated by pneumonia which resolved completely with broad-spectrum antimicrobial therapy. Serial analyses of CMV-PCR and immediate-early antigen (IEAG) of urine, saliva and blood as well as of CMV-specific IgM were negative. The patient was discharged without evidence of GVHD on day +38. Administration of CsA was tapered and stopped on day +105. No pulmonary symptoms were observed at that time. Seven months after SCT he was readmitted with cough and dyspnea. Physical examination, chest X-ray and conventional computed tomography (CT) of the chest were unremarkable. However, PFTs showed extensive decrease of forced vital capacity (FVC), forced expiratory volume in one second (FEV 1 ), FEV 1 as a percentage of the forced vital capacity (FEV 1 /FVC), maximal expiratory flow at 50% remaining vital capacity (MEF 50) and elevation of residual volume (RV) of the lungs consistent with severe AO (Table 1) . Open lung biopsy on day +216 showed only focal lymphoplasmacellular infiltration of bronchioli with moderate extension of the mononuclear infiltrates into the alveolar septae. No interstitial fibrosis, intraluminal or intra-alveolar granulation tissue or necrosis were seen. Microbiologic analyses were negative for bacteria, fungi and viruses. Biopsies of the liver and skin were normal. Immunosuppressive therapy (IST) was restarted on day +216 with i.v. CsA and i.v. pulse-methylprednisolone (8 mg/kg/day) for 3 consecutive days with rapid reduction to 1.6 mg/kg/day every other day. Due to worsening of the respiratory status IST was supplemented by azathioprine (2.7 mg/kg/day) and thalidomide (8 mg/kg/day) beginning on days +249 and +258, respectively. However, no clinical improvement was observed. Follow-up high-resolution (HR)-CTs of the chest on days +258 and +284 revealed bronchiectases with irregular bronchial wall thickening, emphysema and reduction of pulmonary vessels. Radiographic changes affected all lobes and were distributed predominantly in the distal parenchyma. During the following months his pulmonary condition deteriorated slowly. Repeated PFTs showed increasingly severe AO (Table 1) . Antithymocyte globulin (ATG; Pasteur-Merieux, Lyon, France (horse)) (0.8 ml/kg/day from days +351 to +357), low-dose oral CY (1.35 mg/kg/day) from day + 319 and repeated photophereses 21 (days +289, +290, +296, +297, +303, +304, +320, +321, +327, +328) did not have any effect and neither did various bronchodilators. The patient died of respiratory failure on day +476 after SCT. Autopsy was not performed.
Patient 2
A 12-year-old girl underwent induction therapy with cytosine arabinoside (Ara-C) (1400 mg/m 2 total), etoposide (VP-16) (450 mg/m 2 total) and daunorubicin (DNR) (180 mg/m 2 total) for myelodysplastic syndrome (RAEBt) followed by HLA-matched sibling donor peripheral stem cell transplant (PSCT) with 4.8 × 10 6 /kg CD34 + selected cells. Conditioning consisted of BU 145 mg daily on days Ϫ7 to Ϫ4 (16 mg/kg total), CY 2160 mg daily on days Ϫ3 and Ϫ2 (120 mg/kg total) and melphalan 120 mg on day Ϫ1 (100 mg/m 2 ). Additionally, she received 2 × 10 6 /kg CD3 + donor lymphocytes on days +4, +8, +12, +21 post transplant. Pretransplant chest X-ray and PFTs were normal (Table 1) . GVHD prophylaxis was not given during the early post-transplant period. Non-engraftment necessitated a second unmanipulated PSCT (3.56 × 10 8 NC/kg) on day +25 which was supplemented by unmanipulated allogeneic bone marrow (4.6 × 10 8 NC/kg) on day +28 from the same donor. Engraftment (Ͼ1.0 × 10 9 /l leukocytes) was observed by day +33. CsA and steroids (initial i.v. pulse-methylprednisolone with rapid reduction to 0.3 mg/kg/day) were started the day following the second PSCT. The girl developed grade II acute GVHD of the skin and gut by day +57 which resolved quickly after intensification of steroid therapy. Steroids were tapered over 6 weeks and stopped by day +76. Since there was no further evidence of GVHD administration of CsA was tapered and stopped by day +138. A few days later acute GVHD of the skin recurred but again improved rapidly on steroids. No pulmonary symptoms were observed at that time. Elevation of liver enzymes which returned to normal with steroids were interpreted as hepatic GVHD. Liver biopsy performed on day +250 revealed no histopathologic signs of GVHD. On day +194 the patient was readmitted with shortness of breath. Except for tachypnea, physical examination was normal as was chest X-ray. However, severe AO was seen on PFTs (Table 1) . HR-CT of the chest showed patchy polygonal areas of reduced parenchymal attenuation affecting all lobes, characteristic of post-transplant obstructive lung disease. 22 There was no evidence of bronchial wall thickening, bronchial dilatation, intraluminal secretion retention or fibrosis. Open lung biopsy (day +250) revealed only focal and incomplete BO with intraluminal inflammatory granulation tissue and interstitial and peribronchiolovascular infiltrates consisting predominantly of lymphocytes and histiocytes. No interstitial fibrosis, mucosal or transmural necrosis were found. Microbiologic investigations were negative. Since the pulmonary disease did not respond to steroids and CsA the girl additionally received thalidomide (8 mg/kg/day) starting by day +253 and ATG (Pasteur Merieux (horse)) (0.75 ml/kg/day) from days +270 to +277. Stabilization of the respiratory process was observed after administration of ATG. The girl is alive without dyspnea and improving exercise tolerance 15 months after SCT.
Discussion
Symptomatic AO after allogeneic SCT is generally associated with chronic GVHD and responds poorly to IST and bronchodilators. 9, [13] [14] [15] [16] [17] In most cases BO is seen on histopathologic examination, but other morphologic changes of the lungs may also present with AO. 9, 13, [17] [18] [19] Although the first case of fatal GVHD-associated AO was reported two decades ago 13 there are few reports of this complication in childhood. Two children with chronic AO after allogeneic SCT were described in detail by Johnson et al 14 in 1984. In the series by Wyatt et al 15 eight of 64 (13%) SCT recipients developed AO concomitant with chronic GVHD at between 14 and 33 years of age. Three of these patients were 18 years old or younger. 15 Holland et al 17 found BO in seven of 549 patients, representing an overall incidence of only 2%. All patients with BO died, six due to respiratory failure. Remarkably, all patients with BO were 26 years old or younger. No cases of BO were observed in patients without GVHD. 17 A large group of children after SCT was analyzed retrospectively by Schultz et al 9 for development of AO which occurred in 13 of 67 (19.4%) patients. Two of these died of pulmonary failure.
Our two patients presented with a nearly identical clinical course: shortness of breath starting 7-8 months after SCT, severe AO, poor response to treatment and slow progression of the underlying pulmonary process. No pulmonary problems occurred early after SCT. The histopathologic and radiographic abnormalities did not correspond to the clinical picture, particularly with the extremely deteriorated ventilatory function. Patient 1 had an unremarkable conventional chest CT scan after onset of respiratory symptoms.
Although the AO which appears after allogeneic SCT is highly suspicious of chronic lung GVHD, other possible reasons for severely deteriorated ventilatory function must also be considered. Our two patients had normal pretransplant PFTs and no history of bronchial asthma. Antineoplastic treatment before SCT was short (6 months in patient 1 and 6 weeks in patient 2) and did not involve drugs known to be toxic to the lungs except for Ara-C which was administered at a relatively low dose (1.4 g/m 2 ). 23, 24 Toxic lung damage which has been reported after administration of BU and CY was ruled out in our patients by the doses administered, the clinical course, the severe AO and the histopathologic and radiographic findings which were consistent with pulmonary GVHD. [24] [25] [26] [27] [28] Furthermore, conditioning with BU and CY seems to cause only moderate toxicity and transient declines in lung volumes. 27, 28 The possible role of radiation in the development of pulmonary damage was also excluded, since our patients did not receive radiotherapy.
Serial PFTs were introduced to assess the occurrence and degree of lung function impairment in adults and children after SCT. [10] [11] [12] [29] [30] [31] In the series by Curtis et al 29 and Schwarer et al 30 repeated PFTs allowed identification of an obstructive ventilatory defect before the onset of symptoms even in younger patients. GVHD was identified as the main risk factor for developing pulmonary obstructive disease. However, in studies dealing particularly with GVHD-associated AO in childhood and adolescence after SCT, serial PFTs were not performed routinely and prospectively. 9, 17 We conclude from our two patients that the clinical course and the severity of AO after allogeneic SCT cannot be predicted by histopathologic or radiographic findings. In contrast, repeated PFTs gave a much better correlation with the clinical course and the severity of AO. Abnormal ventilatory function preceding symptoms can be detected by serial PFTs, 29, 30 and should therefore be performed routinely even in pediatric patients after SCT. Although many IST regimens are used as therapy for chronic lung GVHD, poor response and high mortality rates are reported in most series. 9, [13] [14] [15] [16] [17] Intensive IST starting at the earliest possible time may control the underlying immunopathologic process better. Serial PFTs used to diagnose GVHD-associated posttransplant AO early could therefore be a simple and useful tool to prompt initiation of IST in the subclinical phase of the disease with the aim of improving the poor long-term outcome of children with pulmonary GVHD.
